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ABSTRACT
Increasing the expression of Hsp70 (heat-shock protein 70)
can inhibit sensory neuron degeneration after axotomy.
Since the onset of DPN (diabetic peripheral neuropathy)
is associated with the gradual decline of sensory neuron
function, we evaluated whether increasing Hsp70 was
sufficient to improve several indices of neuronal function.
Hsp90 is the master regulator of the heat-shock response
and its inhibition can up-regulate Hsp70. KU-32 (N-{7-
[(2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tet-
rahydro-2H-pyran-2-yloxy]-8-methyl-2-oxo-2H-chromen-
3-yl}acetamide) was developed asa novel, novobiocin-based,
C-terminal inhibitor of Hsp90 whose ability to increase
Hsp70 expression is linked to the presence of an acet-
amide substitution of the prenylated benzamide moiety of
novobiocin. KU-32 protected against glucose-induced
death of embryonic DRG (dorsal root ganglia) neurons
cultured for 3 days in vitro. Similarly, KU-32 significantly
decreased neuregulin 1-induced degeneration of myeli-
nated Schwann cell DRG neuron co-cultures prepared
from WT (wild-type) mice. This protection was lost if
the co-cultures were prepared from Hsp70.1 and Hsp70.3
KO (knockout) mice. KU-32 is readily bioavailable and
was administered once a week for 6 weeks at a dose of
20 mg/kg to WT and Hsp70 KO mice that had been
rendered diabetic with streptozotocin for 12 weeks. After
12 weeks of diabetes, both WT and Hsp70 KO mice
developed deficits in NCV (nerve conduction velocity) and
a sensory hypoalgesia. Although KU-32 did not improve
glucose levels, HbA1c (glycated haemoglobin) or insulin
levels, it reversed the NCV and sensory deficits in WT but
not Hsp70 KO mice. These studies provide the first evidence
that targeting molecular chaperones reverses the sensory
hypoalgesia associated with DPN.
Key words: diabetic neuropathy, dorsal root ganglia
neuron, heat-shock protein 70, molecular chaperone, nerve
conduction velocity, neurodegeneration.
INTRODUCTION
DPN (diabetic peripheral neuropathy) is a neurodegenerative
complication of diabetes that has proved difficult to manage
pharmacologically since it does not result from a single
biochemical aetiology that is uniformly manifested for the
disease’s duration (10–30 years). Indeed, small molecule
inhibitors against targets that are relatively diabetes-specific,
i.e. aldose reductase and advanced glycation end products,
have not effectively halted the progressive degeneration of
sensory fibres in human DPN (Tomlinson and Gardiner, 2008).
On the other hand, targeting pathways that contribute to
disease progression, but that are not necessarily diabetes-
specific, has met with some success. For example, oxidative
stress contributes to neuron and glial degeneration in DPN
(Obrosova, 2009) and some small molecule antioxidants have
shown efficacy in reversing clinical and electrophysiological
deficits associated with the disease (Pop-Busui et al., 2006). A
common theme in the above approaches has been the
pharmacological targeting of one specific biochemical
pathology associated with DPN. An alternative and relatively
unexplored paradigm for treating DPN is to up-regulate a
broad cytoprotective response.
Hsp90 (heat-shock protein 90) is the master regulator of
the HSR (heat-shock response) since it binds HSF1 (heat-
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asnneuro.org / Volume 2 (4) / art:e00040 189shock factor 1). Disruption of the Hsp90–HSF1 complex by
cellular stress induces the transcriptional up-regulation of
antioxidant genes and molecular chaperones, such as Hsp70,
that characterize the cytoprotective HSR (Peterson and Blagg,
2009). The induction of molecular chaperones can minimize
the accumulation of damaged proteins by enhancing their
refolding and interfering with pro-apoptotic pathways
(Brown, 2007). Since small-molecule N-terminal Hsp90
inhibitors can mimic cell stress and promote the release of
HSF1 from Hsp90 (Blagg and Kerr, 2006), their ability to
decrease protein aggregation has been proposed for treating
neurodegenerative diseases whose aetiology is linked to the
accumulation of specific misfolded or aggregated proteins
(Luo et al., 2007; Luo et al., 2008). Although the pathogenesis
of DPN is unlikely to result from accumulation of any one
specific misfolded or aggregated protein, hyperglycaemia can
increaseoxidativemodificationofproteins(Akudeet al.,2009).
This can damage protein structure, impair protein folding,
decrease refolding of damaged protein or induce protein
aggregation. Thus chaperone induction by Hsp90 inhibitors
may help to minimize hyperglycaemic stress; however, their
use is potentially complicated by the dual role of Hsp90 in
regulating protein folding.
In the presence of co-chaperones, the folding of nascent
and damaged polypeptides into their biologically active
structures is dependent on Hsp90 and Hsp70. ‘Client proteins’
form a stabilized complex with an Hsp90 homodimer, and ATP
hydrolysis by the chaperone’s intrinsic N-terminal ATPase
provides the energy necessary for conformational maturation
of the client. Inhibiting the chaperone activity of Hsp90
blocks protein folding and leads to client protein degradation
(Powers and Workman, 2007). Since many oncoproteins are
Hsp90 clients, N-terminal Hsp90 inhibitors promote onco-
protein degradation and cytotoxicity (Bishop et al., 2007;
Taldone et al., 2008). Thus Hsp90 inhibitors can be useful as
both chemotherapeutic and neuroprotective agents, and their
primary biological outcome is dictated by the therapeutic
window that dissociates client protein degradation and
cytotoxicity from the cytoprotective induction of an HSR
(Peterson and Blagg, 2009). Although many N-terminal Hsp90
inhibitors have been designed (Pacey et al., 2006), we sought
novel Hsp90 analogues that effectively promote neuropro-
tection in the absence of cytotoxicity.
Novobiocin is an inhibitor of bacterial DNA gyrase that also
exhibits weak affinity for the C-terminal ATP-binding domain
ofHsp90.Sincenovobiocinpromotesclientproteindegradation
at concentrations that also induce an HSR (Marcu et al., 2000a,
2000b; Figure 1A), a systematic modification of novobiocin
was undertaken to identify structure–activity relationships
that yielded high-affinity C-terminal analogues that diverged
client protein degradation from Hsp70 induction (Burlison et al.,
2006; Donnelly et al., 2008). KU-32 (N-{7-[(2R,3R,4S,5R)-3,4-
dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-
yloxy]-8-methyl-2-oxo-2H-chromen-3-yl}acetamide;
Figure 1A) emerged from this library as a potent inducer of
Hsp70, but a poor inducer of client protein degradation.
Importantly, KU-32 was found to be minimally cytotoxic to
primary cortical neurons and protected against neuronal death
induced by amyloid b-peptide (Ansar et al., 2007; Lu et al.,
2008).
Previous work has suggested that Hsp70 can improve the
survival of motor and sensory neurons after axotomy of
neonatal sciatic nerves (Tidwell et al., 2004). However, it is
unknown whether pharmacologically manipulating molecular
chaperones in adult animals is sufficient to improve clinically
relevant indices of unmyelinated and myelinated fibre
function. Since KU-32 inhibits Hsp90 and increases Hsp70
levels, we examined whether it decreased neurodegeneration
of non-myelinated or myelinated sensory neurons in vitro
and attenuated the pathophysiological progression of DPN in
mice. Our results provide compelling evidence that inhibiting
Hsp90 can protect against sensory neuron death and
demyelination and reverse the sensory deficits associated
with DPN. Moreover, Hsp70 expression is critical to this
neuroprotection since its genetic ablation abolished drug
efficacy. These results establish proof-of-principle that
pharmacological modulation of molecular chaperones may
be useful toward decreasing neurodegeneration associated
with the onset of DPN.
MATERIALS AND METHODS
Materials
STZ (streptozotocin) was obtained from Sigma–Aldrich (St.
Louis, MO, U.S.A.). KU-32 and KU-174 (Figure 1A) were syn-
thesized and structural purity was verified as described
previously (Burlison et al., 2006; Donnelly et al., 2008). The
antibodies used and their sources were: SMI-94R (Covance,
Princeton, NJ, U.S.A.); compact myelin protein zero (P0),
ubiquitin C-terminal hydrolase (PGP 9.5; Chemicon, Temecula,
CA, U.S.A.); monoclonal Hsp70 C92F3A-5 (Stressgen, Ann
Arbor, MI, U.S.A.); Akt (also called protein kinase B), b-actin
and horseradish-peroxidase-conjugated secondary antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.); Alexa
FluorH 488 rabbit anti-mouse and Alexa FluorH 568 goat
anti-rabbit antibodies (Molecular Probes, Eugene, OR, U.S.A.).
MCF7 cells were maintained in DMEM (Dulbecco’s modified
Eagle’s medium)-F12 medium containing 10% (v/v) FCS
(fetal calf serum) and 100 units/ml penicillin and 100 mg/ml
streptomycin.
Preparation of non-myelinated and myelinated
DRG (dorsal root ganglion) neurons
DRG neurons were dissected from embryonic day 15–18 rat
pups (Zanazzi et al., 2001) and ganglia were collected into L15
medium and sedimented at 1000 g for 5 min. After
dissociation, the cells were resuspended in serum-free
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supplement, 100 units/ml penicillin, 100 mg/ml streptomycin,
50 mg/ml gentamicin and 50 ng/ml NGF (nerve growth factor;
Harlan Biosciences, Indianapolis, IN, U.S.A.) and seeded at
a density of (2–3)610
4 cells per well. Mitotic cells were
partially depleted by treating the neurons with 10 mM each of
fluorodeoxyuridine and cytosine b-D-arabinoside for 2 days.
The cells were switched to neurobasal medium containing 50
ng/ml NGF and were pretreated for 6 h with the indicated
concentration of KU-32. Hyperglycaemia was induced by the
addition of 20 mM excess glucose (final glucose concentra-
tion 45 mM), and cell viability was assessed after 24 h using
calcein AM (acetoxymethyl ester) and propidium iodide as
previously described (Li et al., 2003).
Schwann cells were isolated from postnatal day 3 rat pups,
and myelinated rat SC-DRGs (Schwann cell DRGs) neuron co-
cultures were prepared as described previously (Yu et al.,
2008). At 3 weeks after initiating myelination, the cultures
were treated with vehicle or 0.1–1 mM KU-32 for 6 h, followed
by 100 ng/ml of NRG1 (human recombinant neuregulin-1-b1
epidermal growth factor domain; amino acids 176–246; R&D
Systems, Minneapolis, MN, U.S.A.). After 48 h, the cultures
were fixed and stained for MBP (myelin basic protein).
Degenerated myelin segments were quantified as previously
described (Yu et al., 2008).
Myelinated mouse neuron cultures were prepared using
DRGs isolated from 1-day-old mouse pups by collecting the
ganglia into L15 medium and dissociating the tissue with
0.25% trypsin at 37˚C for 30 min. The cells were resuspended
in DMEM containing 25 mM glucose and 10% FCS (Atlas
Biologicals, Fort Collins, CO, U.S.A.), triturated with a fire-
polished glass pipette and plated in maintenance medium
(DMEM containing 25 mM glucose, 10% FCS, antibiotics as
above and 50 ng/ml NGF) in the centre of collagen-coated
glass coverslips. Proliferating cells were removed by treating
the neurons with the antimitotics for 3 days. After 1 week in
culture, myelination was induced by the addition of 50 mg/ml
ascorbic acid in maintenan c em e d i u m .T h ec e l l sw e r e
maintained for 15–18 days with medium replenishment
every 2 to 3 days. Demyelination was induced by the addition
of 100–200 ng/ml NRG1 for 2–4 days. Some cultures were
treated overnight with vehicle or the indicated concentration
Figure 1 Structure–activity relationships between novobiocin, KU-32 and KU-174 that diverge client protein degradation from
induction of Hsp70
(a) Structure of analogues and theoretical representation of concentrations affecting client protein degradation (dotted lines) and
chaperone induction (solid lines) for novobiocin (black), KU-32 (blue) and KU-174 (red). (b) KU-32 induces Hsp70 expression but
shows limited degradation of the Hsp90 client protein Akt. (c) KU-174 promotes Akt degradation but does not increase Hsp70 levels.
MCF7 cells were treated with the indicated concentration of inhibitors for 24 h and immunoblot analysis was performed. (d) Band
intensities were normalized to b-actin and expressed as a percentage of the control (n53).
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191of KU-32 prior to the addition of NRG1. The cultures were co-
stained for MBP and PGP9.5 and nuclei were visualized with
DAPI (49,6-diamidino-2-phenylindole). Degeneration of the
myelin segments was quantified with the aid of the open
source imaging software, Cell Profiler (http://www.cellprofiler.
org). Individual myelin internodes were identified using
Otsu’s method for thresholding and segmentation (Otsu,
1979). Segmentation was visually inspected for errors or
regions where segments were closely apposed and manually
edited where necessary. The length was computed for each
identified myelin internode. In cases where segments inter-
sected and a minimum minor axis width was exceeded, lengths
were not included in the average of the population of seg-
ments surveyed. However, total area of coverage for myelin
segments did include the intersecting regions. In some
experiments, cell lysates were prepared and immunoblot
analyses were performed as previously described (Yu et al.,
2008; McGuire et al., 2009).
Induction of diabetes
WT (wild-type) C57Bl/6 and Hsp70.1/70.3 double KO mice
(Hunt et al., 2004) were obtained from Harlan Laboratories
(Indianapolis, IN, U.S.A.) and the Mutant Mouse Resource
Center (San Diego, CA, U.S.A.) respectively. The absence of
Hsp70.1 and 70.3 was confirmed by genotyping and
immunoblot analysis. Eight-week-old WT and Hsp70 mice
were rendered diabetic with three daily doses of STZ (85, 70
and 55 mg/kg; McGuire et al., 2009) and 3 days after the
last injection, mice with FBG (fasting blood glucose).290 mg/dl
were deemed diabetic. After 12 weeks of diabetes, animals were
given a once per week intraperitoneal injection of 5% Captisol
(CyDex Pharmaceuticals, Lenexa, KS,U.S.A.)or 20mg/kg KU-32
in 5% Captisol. All animals were maintained on a 12 h light/
12 h dark cycle with ad libitum access to water and Purina diet
5001 rodent chow. FBG (One-Touch Ultra glucometer) and
HbA1c levels (Act1) were determined prior to killing the
animals.PlasmainsulinlevelsweredeterminedbyELISAusinga
commercial kit from Mercodia AB (Uppsala, Sweden). All
animal procedures were performed in accordance with
protocols approved by the Institutional Animal Care and Use
Committee and in compliance with standards and regulations
for the care and use of laboratory rodents set by the National
Institutes of Health.
Measures of NCV (nerve conduction velocity),
mechanical and thermal sensitivity
MNCV (motor NCV) and SNCV (sensory NCV) measurements
were performed using a TECA
TM Synergy N2-EMG monitoring
system (McGuire et al., 2009). Mechanical sensitivity was
assessed using a Dynamic Plantar aesthesiometer (Stoelting,
Wood Dale, IL, U.S.A.) fitted with a stiff monofilament that
was delivered at an upward force of 8 g. Thermal stimuli
were delivered using a Hargreaves analgesiometer (Hargreaves
et al., 1988). Responses from each animal were measured
three or four times on alternate feet and averaged (McGuire
et al., 2009). After measuring NCV, the animals were killed, and
the sciatic nerves were dissected and flash frozen.
In vivo pharmacokinetics
KU-32 (2 mg/ml) was administered intraperitoneally to 60
Balb/c mice and blood was collected from six mice at the
indicated time via cardiac puncture while the mice were
under isoflurane anaesthesia. The animal was perfused with
saline to remove any residual blood from the organs and the
brain tissue was harvested.
Plasma (0.05 ml) or 0.25 ml brain homogenate was spiked
with trideutero KU-32 as the internal standard, the protein
was precipitated with acetonitrile, KU-32 was extracted from
the supernatant with t-butyl methyl ether and the solvent
was evaporated. Samples were reconstituted with 0.1 ml of
CH3CN/water (20:80) and 0.01 ml was used for LC-MS (liquid
chromatography MS) analysis. Chromatographic separation
was performed using a 5 mmAgilentZorbaxSB2.1mm650 mm
column and a linear gradient of CH3CN/water/formic acid
(5:95:0.2) to CH3CN/water/formic acid (95:5.0:0.1) at a flow
rate of 0.20 ml/min. The effluent was introduced to a Sciex
API3200 Linear Ion Trap detector using turbo ion spray in the
positive mode. Assay response was linear (r
2.0.997) and
validated over the range of 1–1000 ng/ml for plasma samples
and 1–500 ng/ml for mouse brain samples. Recoveries ranged
from 65 to 75%, and PK Solutions software (Summit Research
Services, Montrose, CO, U.S.A.) was used for data analysis.
Statistical analyses
R e s u l t sa r ep r e s e n t e da sm e a n s ¡S.E.M. After verifying
equality of variance, differences between treatments and
genotypes were determined using a one-way or a two-way
ANOVA. Differences between group means were ascertained
using Tukey’s test.
RESULTS
KU-32 decreases cell death and demyelination in
culture models of unmyelinating and myelinating
sensory neurons
KU-32 is a novobiocin-based Hsp90 inhibitor containing an
acetamide substitution on the coumarin ring (Figure 1A). KU-
32 significantly increased the expression of Hsp70 in MCF7
cells at 10 nM, which is consistent with the induction of an
HSR. Although inhibiting Hsp90 can destabilize its association
with client proteins such as Akt and lead to their degradation,
5 mM KU-32 only induced a 35% decrease in the Akt client
(Figures 1B and 1D). In contrast, KU-174 is a novobiocin
analogue in which the acetamide is replaced with a biaryl ring
M.J. Urban and others
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tion and shifted the potency for promoting a 50% decrease
in the Akt client protein from .5 mM for KU-32 to approx.
10 nM for KU-174 (Figures 1C and 1D). Thus substitution of
the prenylated benzamide of novobiocin with the simplified
acetamide is responsible for differentiating client protein
degradation from Hsp70 induction.
Since DPN affects both non-myelinated and myelinated
sensory fibres, we assessed whether KU-32 could protect
cultured sensory neurons against death and demyelination. We
first determined whether KU-32 could protect unmyelinated
embryonic primary sensory neurons from glucose-induced cell
death (Vincent et al., 2005). Rat embryonic DRG neurons were
cultured for 3 days and hyperglycaemia was induced by the
addition of 20 mM excess glucose (45 mM final glucose
concentration) to the medium. Cell death was assessed by the
uptake of propidium iodide. Hyperglycaemia increased neuro-
nal death by ,1.5-fold, but a 6 h pretreatment with either
0.1 or 1 mM KU-32 prevented glucose-induced cell death
(Figure 2A). Regardless of any argumentssurrounding thephysio-
logical relevance of the glucose concentration, these in vitro
data support that targeting molecular chaperones can protect
unmyelinated sensory neurons from acute glucotoxicity.
To ascertain whether KU-32 could protect myelinated
axons against degeneration, we assessed its ability to prevent
NRG1-induced demyelination. Neuregulin-1 is a family of EGF
(epidermal growth factor)-like ligands that bind ErbB
receptors and can induce demyelination of myelinated rat
or mouse SC-DRG neurons (Syed et al., 2010). Myelin
degeneration is readily visualized and quantified by staining
the SC-DRG co-cultures for MBP and assessing the number of
damaged myelin segments (Zanazzi et al., 2001). At 2 days
after treating rat SC-DRG co-cultures with 100 ng/ml NRG1,
the percentage of damaged myelin segments was approx.
33% (Figure 2B). Overnight pretreatment with 1 mM KU-32
was sufficient to prevent this damage. Similarly, KU-32 also
prevented the NRG1-induced decrease in the expression of
the compact myelin protein zero, P0 (Figure 2C). Importantly,
any alterations in client protein levels by KU-32 were not
sufficient to affect viability since 1 mM KU-32 neither
promoted the death of the unmyelinated sensory neurons
(Figure 2A) nor increased the number of damaged myelin
segments in the SC-DRG co-cultures (Figure 2B).
Although KU-32 induces the expression of Hsp70, it
remains unclear whether this protein may be central to its
neuroprotective efficacy. Therefore SC-DRG co-cultures were
prepared from C57BL/6 (WT) and Hsp70.1/70.3 double KO
mice. These two genes represent the inducible forms of
Hsp70, while a related chaperone that is constitutively
expressed, Hsc70 (heat-shock cognate 70 stress protein), is
present at normal levels in these mice (Hunt et al., 2004). WT
cells treated with 200 ng/ml NRG1 for 4 days exhibited a 40%
decrease in the area occupied by myelinated segments
(Figures 3A and 3B). Additionally, the segments showed a
significant shortening of internode length, indicative of an
increased number of breaks due to the ongoing degeneration
Figure 2 KU-32 protects rat sensory neurons against glucose-induced
death and neuregulin-induced demyelination
(a) Embryonic sensory neurons were treated for 6 h with 1% DMSO or 0.1–1
mM KU-32 in a medium containing 25 mM glucose (LG). The glucose
concentration was raised to 45 mM to induce hyperglycaemia (HG) and the
cells were incubated for an additional 24 h. Cell death was assessed using
calcein AM and propidium iodide. *P, 0.05 versus LG control;
‘P,0.003
versus HG; #P,0.02 versus HG (n53). (b) Myelinated rat SC-DRG neuron
co-cultures were treated overnight with 1% DMSO, 0.1 or 1 mM KU-32 and
the cultures treated with PBS or 100 ng/ml NRG1 for 48 h. The myelin
segments were visualized by staining for MBP. Numbers show percentage
degenerated segments in each culture. Results are from a single experiment
performed twice with similar outcomes. (c) Myelinated rat SC-DRG neuron
co-cultures were treated as above and immunoblot analysis for the P0
compact myelin protein was performed. Band intensities were normalized to
b-actin and expressed as a percentage of the control. Results are from one
experiment performed twice with similar outcomes.
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193of the myelin segments (Figure 3C). As above, pretreatment
with 1 mM KU-32 prevented the damage to the myelin
segments formed in cultures from WT mice, and this cor-
related with an increase in Hsp70 levels in the KU-32-treated
cultures (results not shown). On the other hand,
KU-32 was ineffective in preventing NRG1-induced demye-
lination in co-cultures prepared from Hsp70 KO mice
(Figures 3D–3F). As expected, KU-32 did not increase Hsp70
levels in these cultures (results not shown). These results
support the notion that Hsp70 expression is a key component
of the neuroprotective efficacy of KU-32.
KU-32 attenuates the pathophysiological
progression of DPN
The onset of DPN in rodents (3–12 weeks) is characterized by
early metabolic alterations in the conduction velocity of
peripheral nerves and the development of altered sensory
thresholds to noxious thermal (unmyelinated fibres) or
mechanical (myelinated fibres) stimuli presented to the foot.
Since our in vitro readouts support the notion that KU-32
protects unmyelinated and myelinated nerves from death and
degeneration, we rationaliz e dt h a ti tm a yb es i m i l a r l y
protective in a rodent model of DPN.
KU-32 is highly bioavailable and has a systemic clearance of
71.4 ml/min per kg. The drug was detectable to similar levels in
both brain tissue and plasma after intraperitoneal administra-
tion in mice and had a mean half-life (tK) of 105.6 and 106.9
min in plasma and brain respectively (Figure 4A). Although the
accumulation of KU-32 in peripheral nerve has not been
assessed, the level of Hsp70 was modestly increased in sciatic
nerve at 1 week after drug administration (Figure 4B). Pre-
liminary studies indicated that more frequent dosing at these
concentrations did not increase the expression of Hsp70.
Weekly treatment of KU-32 for 6 weeks at both doses did not
alter body weight and showed no confounding affects on
electrophysiological and psychophysical measures that are
diagnostic for the onset of DPN (results not shown). No overt
toxicity was seen at 60 mg/kg, which was the highest dose
tested.
Figure 3 Hsp70 is required for KU-32 to protect against neuregulin-induced demyelination
Myelinated mouse SC-DRG neuron co-cultures were prepared from WT (a–c) or Hsp70 KO (d–f) mice and treated overnight with
vehicle or 1 mM KU-32. The cultures were treated with PBS or 200 ng/ml NRG1 for 4 days and myelin segments were visualized by
staining the cultures for MBP. Total cell number was assessed by staining nuclei with DAPI. Cell profiler was used to calculate the
total segment area and internode length from six fields per six coverslips per treatment. Arrows show examples of internode length.
The results are expressed as fold of the untreated control and are the average of three experiments per genotype. *P, 0.05 versus
KU-32,
‘P,0.05 versus NRG1.
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neurodegeneration is whether it could reverse pre-existing
deficits in SNCV and MNCV, and psychophysical measures of
thermal and mechanical sensitivity. Therefore diabetes was
induced in 8-week-old C57Bl/6 mice and allowed to progress
for 12 weeks prior to drug treatment. Mice then received
vehicle or 20 mg/kg KU-32 once a week for 6 weeks. WT mice
that were diabetic for 3 months developed significant deficits
in MNCV prior to drug treatment (control, 60.4¡2.0 m/s; STZ,
49.5¡6.3 m/s, P, 0.05, Student’s two-tailed t test). While
SNCV declined, it did not yet reach significance (control,
39.3¡2.0 m/s; STZ, 35.8¡1.7 m/s). Importantly, although
both MNCV and SNCV continued to significantly decline after
18 weeks of diabetes, KU-32 prevented this degeneration and
returned NCV to control levels (Figure 5A). Consistent with
the development of a sensory hypoalgesia, diabetic mice also
showed decreased responses to mechanical (Figure 5B) and
thermal (Figure 5C) stimuli. KU-32 treatment also signifi-
cantly improved these deficits in a time-dependent manner
to near control levels after 6 weeks of treatment. It is
important to note that diabetic mice receiving KU-32 showed
no changes in FBG, HbA1c or plasma insulin levels compared
with the diabetic mice receiving vehicle (Table 1). Thus the
improvements in nerve function are not related to decreased
hyperglycaemia or an outright increase in insulin levels.
However, since STZ does not completely ablate insulin
production, we cannot rule out the possibility that KU-32
may improve insulin action (Chung et al., 2008).
The efficacy of KU-32 requires Hsp70
To define the relative contribution of Hsp70 to the efficacy
of KU-32, we examined the effect of diabetes and KU-32
Figure 4 Pharmacokinetic profile of KU-32 uptake in plasma and brain
after intraperitoneal administration
(a) KU-32 (2 mg/ml) was injected intraperitoneally in 5% Captisol, and plasma
andbrainsamplesweretakenattheindicatedtime.KU-32levelswerequantified
byLC-MS.PlasmaAUC0-‘,27 . 4mg/minperml.Resultsarethemeans¡S.E.M.for
six mice per time point. (b) Effect of KU-32 on expression of Hsp70 in sciatic
nerve. Mice were injected with KU-32 and sciatic nerve was harvested after 1
week.Hsp70andb-actinlevelswere determinedby immunoblotting.Thelevel of
Hsp70wasnormalizedtob-actin,andKU-32increasedHsp70expressionby1.2-
and 1.35-fold at 2 and 20 mg/kg respectively.
Figure 5 KU-32 reversed pre-existing indices of diabetic sensory
neuropathy in WT mice
WT mice were rendered diabetic for 12 weeks and then treated with weekly
doses of vehicle or 20 mg/kg KU-32 for 6 weeks. (a) After 18 weeks of
diabetes, MNCV and SNCV significantly decreased in untreated mice, but KU-
32 treatment for 6 weeks improved the deficits in both MNCV and SNCV.
*P,0.01 versus time-matched untreated control;
‘P,0.001 versus 18 week
STZ+vehicle. Two weeks after the induction of diabetes, mechanical
sensitivity (b) and thermal sensitivity (c) were assessed weekly. Twelve
weeks of diabetes produced a significant mechanical and thermal hypoalgesia
and weekly treatment with KU-32 induced a time-dependent improvement in
both sensory thresholds to near control levels. Since the sensory measures
in the diabetic mice became more variable after 14 weeks, this time point
was used for statistical comparisons. *P,0.05 compared with the time-
matched control.
‘P,0.05 compared with STZ+vehicle at 14 weeks.
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195treatment on the development of DPN in the Hsp70 KO mice.
Hsp70 KO mice (C57Bl/6 background) readily developed
diabetes and showed no differences in blood glucose or
HbA1c levels after 18 weeks of diabetes compared with
diabetic C57Bl/6 mice (Table 1). Diabetic Hsp70 KO mice also
developed significant deficits in MNCV and SNCV (Figure 6A)
that mirrored those seen in WT mice. Compared with WT
mice, genetic deletion of Hsp70 did not alter the severity of
the deficits in mechanical (Figure 6B) and thermal sensitivity
(Figure 6C) that had developed prior to drug treatment. Thus
the Hsp70 KO mice respond to diabetes in a manner very
similar to that observed in WT mice. However, weekly dosing
of the diabetic Hsp70 KO mice with 20 mg/kg KU-32 was
unable to correct the deficits in NCV or mechanical and
thermal sensitivities. Consistent with the in vitro data, these
results provide strong support that Hsp70 plays a central role
in the neuroprotective efficacy of KU-32.
DISCUSSION
Targeting molecular chaperones has shown promising results
in treating both neurodegenerative and diabetes-associated
phenotypes. For example, N-terminal Hsp90 inhibitors
decreased motor neuron degeneration in a murine model of
spinal and bulbar muscular atrophy (Waza et al., 2005) and
reduced aggregated or hyperphosphorylated forms of tau
protein in JNPL3 mice (Luo et al., 2007) and humanized tau
protein transgenic mice (Dickey et al., 2007). Similarly,
induction of Hsp70 with HSF1 activators (bimoclomol and
related hydroxylamine derivatives) improved insulin resist-
ance (Chung et al., 2008), diabetic wound healing (Atalay et
al., 2009; Vigh et al., 1997) and was sufficient to prevent the
slowing of NCV in diabetic rats (Biro et al., 1997). In the
present study, we provide the first evidence that a novel C-
terminal Hsp90 inhibitor that increases Hsp70 expression is
similarly effective in preventing death of unmyelinated
neurons, demyelination of myelinated sensory neurons and
was able to reverse pre-existing sensory deficits associated
with the development of DPN in mice.
Hsp70 is a critical mechanistic component necessary for the
efficacy of KU-32 in improving a major neurodegenerative
complication of diabetes. However, the molecular basis by
which Hsp70 intersects with biochemical mediators that
contribute to the pathophysiology of DPN is unclear. It is well
recognized that induction of the HSR can up-regulate
numerous genes that may have a beneficial effect in
ameliorating DPN, i.e. Mn superoxide dismutase and haem
oxygenase 1. The reliance on Hsp70 expression for neuropro-
tection suggests that if KU-32 promotes a broader HSR via the
release of HSF-1, this is not sufficient for drug efficacy.
Previous work has shown that up-regulation of Hsp70 can
improve insulin resistance and that this is associated with a
decrease in phosphorylation of JNK (c-Jun N-terminal kinase)
(Chung et al., 2008). Although increasing the expression of
Hsp70 inhibits JNK-dependent apoptosis (Bienemann et al.,
2008; Salehi et al., 2006), neuronal apoptosis is not a
substantial contributing feature to the pathophysiology of
DPN (Cheng and Zochodne, 2003). Indeed, adult neurons are
relatively insensitive to JNK-induced apoptosis (Walsh et al.,
2004). However, JNK activation does mediate death of
embryonic neurons (Bienemann et al., 2008; Salehi et al.,
2006; Walsh et al., 2004), and the ability of Hsp70 to block this
activity may protect against glucose-induced death of the
immature, embryonic DRG neurons. Interestingly, although
increased expression of the c-jun transcription factor con-
tributes to NRG1-induced demyelination, its phosphorylation
by JNK is not essential to mediate Schwann cell degeneration
(Parkinson et al., 2008). These results suggest that any
inhibitory effect of Hsp70 on JNK activity would not be
critical to the ability of KU-32 to attenuate demyelination.
However, an interaction of Hsp70 with JNK is possible in the
context of DPN, since JNK activity increases in diabetic nerves
(Fernyhough et al., 1999; Purves et al., 2001) and contributes
to features of neuropathic pain (Gao and Ji, 2008). Thus up-
regulating Hsp70 may be an effective treatment for both
insensate and painful diabetic neuropathy.
The ability of Hsp70 to refold aggregated or oxidatively
damaged proteins may also contribute to improving nerve
function. It is generally accepted that enhanced production
of reactive oxygen species and subsequent mitochondrial
dysfunction (Verkhratsky and Fernyhough, 2008) and fission
(Figueroa-Romero et al., 2009; Leinninger et al., 2006)
contribute to DPN. Oxidative modification of the mitochon-
drial fission protein Drp1 (dynamin-related protein 1) by
S-nitrosylation favours the formation of Drp1 tetramers and
Table 1 FBG, HbA1C and insulin levels in WT and Hsp70 KO mice
*P,0.05 versus vehicle+vehicle; {P,0.05 versus vehicle+KU-32; n.d., not determined.
Treatment FBG (mg/dl) HbA1C (%) Insulin (nM) n
WT mice
Vehicle+vehicle 136¡4 4.7¡0.1 0.25¡0.04 11
Vehicle+KU-32 121¡4 4.6¡0.2 0.34¡0.06 11
STZ+vehicle 389¡83* 11.4¡0.6* 0.1¡0.004* 3
STZ+KU-32 450¡13{ 11.6¡0.3{ 0.11¡0.006{ 6
Hsp70 KO mice
Vehicle+vehicle 115¡5 4.9¡0 n.d. 5
Vehicle+KU-32 119¡11 4.8¡0.1 n.d. 7
STZ+vehicle 380¡45* 10.9¡0.5* n.d. 4
STZ+KU-32 412¡33{ 10.9¡0.8{ n.d. 5
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which promotes mitochondrial fission (Nakamura and Lipton,
2010). It will be important to determine whether an
interaction of Hsp70 with Drp1 may aid its refolding or
prevent aggregation to minimize increased GTPase activity
and organelle fission. However, Hsp70 mutants that are
folding-incompetent, but are able to bind and maintain the
solubility of denatured proteins, were as effective as WT Hsp70
in decreasing oxidativestress and the rate ofprotonleak across
the inner mitochondrial membrane in glucose-deprived
astrocytes (Ouyang et al., 2006). Thus the folding competence
of Hsp70 may not be a critical feature of neuroprotection, at
least in transient models of oxidative stress that are not
associated with protein aggregation. On the other hand, Hsp70
may also help maintain mitochondrial protein integrity via its
interaction with TOM70 (translocase of outer membrane 70),
which is important for mitochondrial protein import (Young
et al., 2003).
It is notable that the diabetic Hsp70 KO mice developed a
similarly severe neuropathy as was observed in the WT mice.
This outcome indicates that inducible forms of Hsp70 are not
necessary for the pathogenesis and progression of neuropathy.
However, since constitutive forms of Hsp70 (Hsc70) may
substitute for Hsp70.1 and 70.3, we cannot rule out the
possibility that diabetes-induced changes in chaperone activity
may contribute to decreased neuronal function. Indeed, the
effect of diabetes on Hsp70 protein expression and its role
in the development of diabetic complications are not clear. In
short-term diabetic rats (1 month), Hsp70 levels did not change
in various skeletal muscles, heart, liver or kidney (Najemnikova
et al., 2007). However, diabetes may affect Hsp70 in a cell-
selective manner since immunoreactivity increased in the
kidney outer medulla, but not the glomeruli, of rats rendered
diabetic for 4–24 weeks (Barutta et al., 2008). Unfortunately,
whether this contributed to the nephropathy that developed in
these animals was not determined. Similarly, some reports
indicate that a 15 min heat stress enhanced the expression
of Hsp70 in diabetic heart relative to levels observed in heat-
stressed non-diabetic rats (Najemnikova et al., 2007). In
contrast, induction of Hsp70 has been reported to be similar
in hearts from heat stressed control and diabetic rats and that
Hsp70 induction in diabetic heart was not cardioprotective
against an ischaemia/reperfusion injury (Joyeux et al., 1999).
These resultsraise the issue of whether Hsp70 induction may be
broadly protective in reversing diabetic complications assoc-
iatedwithotherorgans.However,tothebestofourknowledge,
the potential efficacy of Hsp90 inhibitors and Hsp70 induction
against other diabetic complications has not been adequately
examined.
In summary, the present study provides proof-of-principle
that pharmacologically targeting molecular chaperones can
be sufficiently cytoprotective to reverse pre-existing symp-
toms associated with insensate DPN in experimental animals.
The potential of this approach as a monotherapy or in
conjunction with pharmacological agents that antagonize a
specific biochemical pathology that contributes to DPN may
broaden our translational options toward developing effec-
tive therapies for the medical management of DPN.
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Figure 6 Hsp70 is required for the in vivo efficacy of KU-32 against
indices of diabetic sensory neuropathy
Hsp70 KO mice were rendered diabetic for 12 weeks and then treated with
weekly doses of vehicle or 20 mg/kg KU-32 for 6 weeks. (a) After 18 weeks of
diabetes, MNCV and SNCV decreased in vehicle-treated mice and weekly
treatment with KU-32 for 6 weeks did not reverse these deficits. *P,0.01
versus untreated control;
‘P,0.01 versus vehicle+KU-32. Two weeks after
the induction of diabetes, mechanical sensitivity (b) and thermal sensitivity
(b) were assessed weekly. Although 12 weeks of diabetes produced a
significant mechanical and thermal hypoalgesia, weekly treatment with KU-
32 had no effect on improving the sensory thresholds.*P,0.01 compared
with the time-matched untreated control.
‘P,0.01 compared with time-
matched vehicle+KU-32.
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